Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00412893 · ClinicalTrials.gov registry record · Phase 3
Isavuconazole (BAL8557) for Primary Treatment of Invasive Aspergillosis
A Phase 3 study, sponsored by Astellas Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 527
- Enrollment target
NCT00412893 is a Phase 3 study that has completed, run by Astellas Pharma. The registered enrollment target is 527 participants.
The verdict
NCT00412893, a Phase 3 study, has completed, sponsored by Astellas Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 527 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the efficacy and safety of isavuconazole versus voriconazole in the treatment of patients with invasive aspergillosis.
Interventions
- DRUG Isavuconazole
- DRUG Voriconazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 527 participants |
| Start Date | 2007-03-07 |
| Est. Completion | 2013-03-28 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00412893
The ClinicalTrials.gov registry entry for NCT00412893 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 527 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma, which has 165 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Isavuconazole is the first listed.
NCT00412893 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00412893 about?
NCT00412893 is a clinical study titled "Isavuconazole (BAL8557) for Primary Treatment of Invasive Aspergillosis". The purpose of this study is to compare the efficacy and safety of isavuconazole versus voriconazole in the treatment of patients with invasive aspergillosis.
What is the current status of trial NCT00412893?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 527 participants. The study started on 2007-03-07. Estimated completion is 2013-03-28.
What interventions are being tested in trial NCT00412893?
The interventions under investigation include: Isavuconazole (DRUG), Voriconazole (DRUG).
Who is sponsoring clinical trial NCT00412893?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.